1
John G Curd, Lori A Kunkel, Antonio J Grillo Lopez: Treatment of autoimmune diseases. Biogen Idec, Genentech, Sidley Austin, October 26, 2010: US07820161 (61 worldwide citation)

Methods are disclosed of treating rheumatoid arthritis in a human comprising administering to the human more than one intravenous dose of a therapeutically effective amount of rituximab and administering methotrexate to the human.


2
John G Curd, Antonio J Grillo Lopez: Treatment of vasculitis. Genentech, Biogen Idec, Wendy M Lee, October 1, 2013: US08545843 (32 worldwide citation)

The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.


3

4
Christine A White, Antonio J Grillo Lopez: Treatment of diffuse large-cell lymphoma with anti-CD20 antibody. Biogen, Wendy Lee, Ginger R Dreger, Arnold & Porter, November 29, 2016: US09504744 (1 worldwide citation)

The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaun ...


5
Antonio J Grillo Lopez: Intrathecal administration of rituximab for treatment of central nervous system lymphomas. IDEC Pharmaceuticals Corporation, Pillsbury Winthrop, January 24, 2002: US20020009444-A1 (1 worldwide citation)

This invention describes methods of using anti-B cell antibodies, preferably anti-CD20 antibodies, and most preferably Rituximab, to treat B cell lymphomas of the brain, especially primary central nervous system lymphomas (PCNSLs), and to prevent meningeal relapse. The antibodies can be administered ...


6
Antonio J Grillo Lopez: Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody. Biogen, Ginger R Dreger, October 30, 2018: US10113000

New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas.


7
Antonio J Grillo Lopez, John Leonard: Use of chimeric anti-CD20 antibody as in vitro or in vivo purging agent in patients receiving BMT or PBSC transplant. Idec Pharmaceuticals Corporation, Pillsbury Winthrop, October 28, 2004: US20040213784-A1

The use of a chimeric anti-CD20 antibody, RITUXAN®, as an in vivo or in vitro purging agent, of patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related malignancies, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraft ...


8
Antonio J Grillo Lopez: Combination therapies for B-cell lynphomas comprising administration of anti-CD20 antibody. IDEC Pharmaceuticals Corporation, Pillsbury Winthrop, November 6, 2003: US20030206903-A1

New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.


9
Antonio J Grillo Lopez: Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody. Biogen Idec, Sidley Austin, February 14, 2008: US20080038261-A1

New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.


10
Antonio J Grillo Lopez: Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody. IDEC Pharmaceuticals Corporation, Pillsbury Winthrop, February 6, 2003: US20030026804-A1

New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.